country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-186398

Copy Link Print Information

Anticancer agent-375

Anticancer agent-375 is an anticancer agent that downregulates mTOR expression and signaling, relieves mTOR-mediated autophagy inhibition, and induces autophagy. Anticancer agent-375 inhibits AKT expression, survival signaling, and STAT family signaling involved in survival and metastasis. Anticancer agent-375 induces apoptosis through activation of the mitochondrial pathway and inhibits cell migration, adhesion, and colony formation. Anticancer agent-375 inhibits cancer cell viability and proliferation and induces cytotoxicity. Anticancer agent-375 can be used in research related to colorectal cancer and breast cancer.

For research use only. We do not sell to patients.

CAS No.: 2379553-98-5
Formula: C₁₇H₁₉BrN₂O
Molecular Weight:347.25

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (290 KB)

Anticancer agent-375 Chemical Structure

CAS No.: 2379553-98-5

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All mTOR Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC50	8.2 μM	Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction by MTT assay. Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction by MTT assay.	download_pub
4T1	IC50	6.4 μM	Antiproliferative activity against mouse 4T1 cells assessed as viability reduction by MTT assay. Antiproliferative activity against mouse 4T1 cells assessed as viability reduction by MTT assay.	download_pub
HT-29	IC50	3.7 μM	Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay. Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay.	download_pub
DLD-1	IC50	7.2 μM	Antiproliferative activity against human DLD-1 cells assessed as viability reduction by MTT assay. Antiproliferative activity against human DLD-1 cells assessed as viability reduction by MTT assay.	download_pub
DLD-1	IC50	9.19 μM	Cytotoxicity against human DLD-1 cells by MTT assay as an earlier reported IC50. Cytotoxicity against human DLD-1 cells by MTT assay as an earlier reported IC50.	download_pub

In Vitro

Anti-cancerApoptosisAutophagy

Anti-cancer

Anticancer agent-375 (Compound 3a) (1-160 µM; 48-72 h) reduces the viability of MDA-MB-231, 4T1, HT-29, and DLD-1 cells, with the lowest IC₅₀ of 3.7 µM in HT-29 cells^[1].
Anticancer agent-375 (48 h) inhibits wound closure and lateral migration of HT-29 cells^[1].
Anticancer agent-375 (24 h) reduces the cell adhesion of HT-29 cells^[1].
Anticancer agent-375 inhibits colony formation in HT-29 cells^[1].

Anti-cancer

Apoptosis

Anticancer agent-375 (3.7-7.2 µM; 48 h) induces apoptosis in HT-29 and DLD-1 cells at IC₅₀ concentrations^[1].

Anti-cancer

Apoptosis

Autophagy

Anticancer agent-375 (3.7 µM; 48 h) shifts gene expression in HT-29 cells toward apoptosis and inhibits AKT/Stat3/Mtor and adhesion markers^[1].

Anti-cancer

Autophagy

Anticancer agent-375 increases LC3 immunofluorescence and decreases mTOR immunofluorescence in HT-29 and DLD-1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MDA-MB-231, 4T1, HT-29, and DLD-1 cell lines
Concentration:

1, 5, 10, 20, 40, 80 and 160 µM
Incubation Time:

48 h or 72 h
Result:

Suppressed proliferation dose-dependently in HT-29 and DLD-1 cells.
IC50 values were 8.2 µM in MDA-MB-231, 6.4 µM in 4T1, 3.7 µM in HT-29, and 7.2 µM in DLD-1.
An earlier MTT IC50 was 9.19 µM in DLD-1.

Apoptosis Analysis^[1]

Cell Line:

HT-29 and DLD-1 colorectal cancer cells
Concentration:

3.7 µM (HT-29); 7.2 µM (DLD-1)
Incubation Time:

48 h
Result:

Produced a significant shift from the viable cell population to the apoptotic population in both HT-29 and DLD-1 cells.

Real Time qPCR^[1]

Cell Line:

HT-29 colorectal cancer cells
Concentration:

3.7 µM
Incubation Time:

48 h
Result:

BAX and Caspase-3 mRNA levels increased, while BCL2 decreased.
AKT, Stat3, and Mtor expression decreased.
BECN1 showed an increased trend.
ITGβ1 and VIM were downregulated.

Related Protocols :

Chemical Information

CAS No. 2379553-98-5
Molecular Weight 347.25
Formula C₁₇H₁₉BrN₂O
SMILES

OCCN1C=[N+](CC2=CC=C(C)C=C2)C3=C1C=CC=C3.[Br-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Çakır M, et al. Anticancer Effects of a Benzimidazole Derivative in Colorectal Cancer Cells: Involvement of Autophagy and Apoptosis[J]. 2026.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Anticancer agent-375

All mTOR Isoforms

All Akt Isoforms